• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

铜死亡相关长链非编码RNA在甲状腺癌预后及免疫治疗中的潜在作用

Potential Role of Cuproptosis-Related Lncrna in Prognosis and Immunotherapy of Thyroid Carcinoma.

作者信息

Cai Yunying, Niu Ben, Gao Jie, Su Heng

机构信息

Department of Endocrinology and Metabolism, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, China.

出版信息

Iran J Public Health. 2023 May;52(5):995-1007. doi: 10.18502/ijph.v52i5.12718.

DOI:10.18502/ijph.v52i5.12718
PMID:37484723
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10362200/
Abstract

BACKGROUND

Cuproptosis-related long non-coding RNA (lncRNA) disease is associated with the development and progression of tumors. We aimed to investigate the prediction of cuproptosis-related lncRNA on the prognosis and immunotherapy of patients with thyroid carcinoma (THCA).

METHODS

The thyroid cancer-associated expression data and lnc RNAs data were downloaded from The Cancer Genome Atlas (TCGA) and Ensembl database. The prognostic model of cuproptosis-related lncRNAs was successfully constructed through Lasso regression analysis and Cox regression analysis. Then, the prognostic value of prognostic model of cuproptosis-related lncRNAs was tested through the survival analysis, ROC curves and nomographic charts. Finally, the prognostic model of cuproptosis-related lncRNAs associated with immunity and mutational load of tumors was analyzed, and potential targeted drugs for THCA were predicted.

RESULTS

A cuproptosis-related lncRNA model of THCA (AC026100.1, AF235103.3, LNCSRLR) was successfully constructed, which has an independent prognostic value. Moreover, the cuproptosis-related lncRNA model was associated with immune signatures and mutational load in most tumors, showing its high correlation with the sensitivity of targeted drugs such as 5-Fluorouracil, Bleomycin, Rapamycin and Sunitinib.

CONCLUSION

The cuproptosis-related lncRNA model of THCA has promising applications in the treatment and prognosis of THCA.

摘要

背景

铜死亡相关长链非编码RNA（lncRNA）疾病与肿瘤的发生发展相关。我们旨在研究铜死亡相关lncRNA对甲状腺癌（THCA）患者预后及免疫治疗的预测作用。

方法

从癌症基因组图谱（TCGA）和Ensembl数据库下载甲状腺癌相关表达数据和lncRNAs数据。通过Lasso回归分析和Cox回归分析成功构建铜死亡相关lncRNAs的预后模型。然后，通过生存分析、ROC曲线和列线图检验铜死亡相关lncRNAs预后模型的预后价值。最后，分析与肿瘤免疫和突变负荷相关的铜死亡相关lncRNAs预后模型，并预测THCA的潜在靶向药物。

结果

成功构建了THCA的铜死亡相关lncRNA模型（AC026100.1、AF235103.3、LNCSRLR），该模型具有独立的预后价值。此外，铜死亡相关lncRNA模型与大多数肿瘤的免疫特征和突变负荷相关，显示出其与5-氟尿嘧啶、博来霉素、雷帕霉素和舒尼替尼等靶向药物敏感性的高度相关性。

结论

THCA的铜死亡相关lncRNA模型在THCA的治疗和预后方面具有广阔的应用前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/f3564c671b7e/IJPH-52-995-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/44b2aa84b352/IJPH-52-995-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/078669c37faa/IJPH-52-995-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/5f4d3820b3c2/IJPH-52-995-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/1436c0afa730/IJPH-52-995-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/d2c554c1f287/IJPH-52-995-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/70d421789adf/IJPH-52-995-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/b1cc0c2ad8b2/IJPH-52-995-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/1a93a586ac87/IJPH-52-995-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/f3564c671b7e/IJPH-52-995-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/44b2aa84b352/IJPH-52-995-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/078669c37faa/IJPH-52-995-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/5f4d3820b3c2/IJPH-52-995-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/1436c0afa730/IJPH-52-995-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/d2c554c1f287/IJPH-52-995-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/70d421789adf/IJPH-52-995-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/b1cc0c2ad8b2/IJPH-52-995-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/1a93a586ac87/IJPH-52-995-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32cb/10362200/f3564c671b7e/IJPH-52-995-g009.jpg

相似文献

1
Potential Role of Cuproptosis-Related Lncrna in Prognosis and Immunotherapy of Thyroid Carcinoma.铜死亡相关长链非编码RNA在甲状腺癌预后及免疫治疗中的潜在作用
Iran J Public Health. 2023 May;52(5):995-1007. doi: 10.18502/ijph.v52i5.12718.
2
Cuproptosis-related lncRNAs predict prognosis and immune response of thyroid carcinoma.铜死亡相关长链非编码RNA预测甲状腺癌的预后和免疫反应。
Front Genet. 2023 Jul 4;14:1100909. doi: 10.3389/fgene.2023.1100909. eCollection 2023.
3
Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.可有效预测肝细胞癌预后的铜死亡相关长链非编码RNA模型。
World J Gastrointest Oncol. 2022 Oct 15;14(10):1981-2003. doi: 10.4251/wjgo.v14.i10.1981.
4
Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.铜死亡相关 lncRNA 预测肺腺癌的预后和免疫反应。
World J Surg Oncol. 2022 Sep 1;20(1):275. doi: 10.1186/s12957-022-02727-7.
5
Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.基于铜死亡相关 lncRNAs 的子宫内膜癌预后特征构建和免疫治疗反应分析。
Comput Biol Med. 2023 Jun;159:106905. doi: 10.1016/j.compbiomed.2023.106905. Epub 2023 Apr 11.
6
Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.构建并验证一种与铜死亡相关的长链非编码RNA特征作为结肠癌的新型稳健预后模型。
Front Oncol. 2022 Jul 28;12:961213. doi: 10.3389/fonc.2022.961213. eCollection 2022.
7
A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.一种新型的铜死亡相关长链非编码RNA特征：对急性髓系白血病的预后和治疗价值
Front Oncol. 2022 Oct 7;12:966920. doi: 10.3389/fonc.2022.966920. eCollection 2022.
8
Construction of prognostic risk model of bladder cancer based on cuproptosis-related long non-coding RNAs.基于铜死亡相关长非编码 RNA 的膀胱癌预后风险模型的构建。
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023 Apr 25;52(2):139-147. doi: 10.3724/zdxbyxb-2022-0539.
9
The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.与铜死亡相关的长链非编码RNA特征作为肾透明细胞癌免疫治疗和药物筛选中预后的新型生物标志物。
Front Genet. 2023 Jan 23;14:1039813. doi: 10.3389/fgene.2023.1039813. eCollection 2023.
10
Development and verification of a newly established cuproptosis-associated lncRNA model for predicting overall survival in uterine corpus endometrial carcinoma.一种新建立的用于预测子宫体子宫内膜癌总生存期的铜死亡相关长链非编码RNA模型的开发与验证
Transl Cancer Res. 2023 Aug 31;12(8):1963-1979. doi: 10.21037/tcr-23-61. Epub 2023 Aug 28.

引用本文的文献

1
Dual roles of long non-coding RNAs in thyroid cancer: regulation of programmed cell death pathways.长链非编码RNA在甲状腺癌中的双重作用：对程序性细胞死亡途径的调控
Med Oncol. 2025 May 23;42(6):217. doi: 10.1007/s12032-025-02750-0.
2
Copper Chelation Therapy Attenuates Periodontitis Inflammation through the Cuproptosis/Autophagy/Lysosome Axis.铜螯合疗法通过铜死亡/自噬/溶酶体轴减轻牙周炎炎症。
Int J Mol Sci. 2024 May 28;25(11):5890. doi: 10.3390/ijms25115890.

本文引用的文献

1
Development and validation of a novel endoplasmic reticulum stress-related lncRNA prognostic signature and candidate drugs in breast cancer.一种新型内质网应激相关lncRNA预后标志物及乳腺癌候选药物的开发与验证
Front Genet. 2022 Aug 25;13:949314. doi: 10.3389/fgene.2022.949314. eCollection 2022.
2
A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.一个新的铜死亡相关预后基因特征，并在透明细胞肾细胞癌中验证差异表达。
Genes (Basel). 2022 May 10;13(5):851. doi: 10.3390/genes13050851.
3
Cuproptosis: Cellular and molecular mechanisms underlying copper-induced cell death.
铜死亡：铜诱导细胞死亡的细胞和分子机制。
Mol Cell. 2022 May 19;82(10):1786-1787. doi: 10.1016/j.molcel.2022.05.001.
4
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.欧洲肿瘤内科学会（ESMO）关于晚期甲状腺癌全身治疗应用的临床实践指南更新
Ann Oncol. 2022 Jul;33(7):674-684. doi: 10.1016/j.annonc.2022.04.009. Epub 2022 Apr 28.
5
Clinicopathological and Molecular Features of Secondary Cancer (Metastasis) to the Thyroid and Advances in Management.甲状腺继发癌（转移）的临床病理和分子特征及治疗进展。
Int J Mol Sci. 2022 Mar 17;23(6):3242. doi: 10.3390/ijms23063242.
6
Copper induces cell death by targeting lipoylated TCA cycle proteins.铜通过靶向脂酰化 TCA 循环蛋白诱导细胞死亡。
Science. 2022 Mar 18;375(6586):1254-1261. doi: 10.1126/science.abf0529. Epub 2022 Mar 17.
7
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020.全球甲状腺癌的流行病学概况：2020 年发病率和死亡率的 GLOBOCAN 估计。
Lancet Diabetes Endocrinol. 2022 Apr;10(4):264-272. doi: 10.1016/S2213-8587(22)00035-3. Epub 2022 Mar 7.
8
Necroptosis-related lncRNA to establish novel prognostic signature and predict the immunotherapy response in breast cancer.基于 necroptosis 相关 lncRNA 构建新型预后标志物并预测乳腺癌免疫治疗反应。
J Clin Lab Anal. 2022 Apr;36(4):e24302. doi: 10.1002/jcla.24302. Epub 2022 Mar 1.
9
Signature of m5C-Related lncRNA for Prognostic Prediction and Immune Responses in Pancreatic Cancer.用于胰腺癌预后预测和免疫反应的m5C相关长链非编码RNA的特征
J Oncol. 2022 Feb 15;2022:7467797. doi: 10.1155/2022/7467797. eCollection 2022.
10
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).塞尔美替尼联合辅助放射性碘治疗高危分化型甲状腺癌患者的 III 期随机安慰剂对照试验（ASTRA）。
J Clin Oncol. 2022 Jun 10;40(17):1870-1878. doi: 10.1200/JCO.21.00714. Epub 2022 Feb 22.